Sign in
WithdrawnPhase 2

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

Key facts

Who runs it
Gannex Pharma Co., Ltd.
Trial code
Status
Withdrawn
Phase
Phase 2
Started
1 Dec 2023
Ended
9 Jan 2025
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ASC41 2 mg
  • ASC41 4 mg
  • Placebo
Record updated
27 September 2024
Why it stopped
This study has been cancelled due to business reasons

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Presence of ≥ 8% liver fat content on screening MRI-PDFF
  • Histologic evidence of NASH upon central read of a liver biopsy obtained no more than 6 months before Day 1 defined by NASH activity score (NAS) greater than or equal to 4 with at least 1 point each in inflammation and ballooning
  • Diabetes Mellitus well controlled based on laboratory test HbA1c ≤ 9.5%

Who cannot take part

  • Treatment with vitamin E (unless stable dose of < 400 IU/d), thiazolidinediones (TZD), or glucagon-like peptide-1 receptor agonists (GLP-1 RA), unless subject is on a stable dose for 6 months prior to qualifying liver biopsy
  • Use of any investigational drug within 6 months of MRI-PDFF and/or liver biopsy
  • Evidence of advanced liver disease such as cirrhosis (stage 4 fibrosis) or decompensated liver disease (e.g. ascites, esophageal varices) or liver cancer
  • Evidence of other causes of chronic liver disease
  • Known history of alcohol or other substance abuse within the last year or at any time during the study
  • Known positivity for antibody to Human Immunodeficiency Virus (HIV)
  • Weight change ≥ 5% after qualifying liver biopsy or MRI-PDFF performed
  • Any contraindications to a MRI scan

About the trial

What the trial wants to find out

This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults with NASH.

The 4 groups in the trial

  • Part 1-ASC41 2mgTreatment being tested

    ASC41 2mg for 52 weeks.

    Treatment: ASC41 2 mg

  • Part1-placeboPlacebo, for comparison

    Matching placebo for 52 weeks.

    Treatment: Placebo

  • Part 2-ASC41 4mgTreatment being tested

    ASC41 4 mg for 52 weeks.

    Treatment: ASC41 4 mg

  • Part2-placeboPlacebo, for comparison

    Matching placebo for 52 weeks.

    Treatment: Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Seamless Phase 2a/2b, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41, a Thyroid Hormone Receptor β Agonist, in Adults With Nonalcoholic Steatohepatitis (NASH)
Record updated
27 September 2024